Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)

PHASE3CompletedINTERVENTIONAL
Enrollment

820

Participants

Timeline

Start Date

November 30, 2008

Primary Completion Date

July 31, 2010

Study Completion Date

January 31, 2011

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

exenatide once weekly

subcutaneous injection, 2mg, once weekly plus placebo oral once daily

DRUG

metformin

oral, 1000-2500mg, daily plus placebo once weekly subcutaneous injection

DRUG

sitagliptin

oral, 100 mg, daily plus placebo once weekly subcutaneous injection

DRUG

pioglitazone

oral, 30-45mg, daily plus placebo once weekly subcutaneous injection

Trial Locations (106)

Unknown

Research Site, Buena Park

Research Site, Los Angeles

Research Site, Valencia

Research Site, Jacksonville

Research Site, Atlanta

Research Site, Meridian

Research Site, Des Moines

Research Site, Grand Rapids

Research Site, Minneapolis

Research Site, Billings

Research Site, Toms River

Research Site, Wilmington

Research Site, Danville

Research Site, Philadelphia

Research Site, Wilke Barre

Research Site, Austin

Research Site, El Paso

Research Site, New Branufels

Research Site, Buenos Aires

Research Site, Mar del Plata

Research Site, Leuven

Research Site, Marchovelette

Research Site, Tessenderlo

Research Site, Brasília

Research Site, Campinas

Research Site, Curitiba

Research Site, Fortaleza

Research Site, Joinville

Research SIte, Porto Alegre

Research Site, Recife

Research Site, São Paulo

Research Site, Coquitlam

Research Site, Penticton

Research Site, Ottawa

Research Site, Gatineu

Research Site, Mississauga

Research Site, Petitcodiac

Research Site, Pointe-Claire

Research Site, Regina

Research Site, Saint John

Research Site, Châteaugiron

Research Site, Mûrs-Erigné

Research Site, Nantes

Research Site, Vieux-Condé

Research Site, Dresden

Research Site, Mainz

Research Site, Münster

Research Site, Rodgau

Research Site, Budapest

Research Site, Gyula

Research Site, Hódmezővásárhely

Research Site, Pécs

Research Site, Ahmedabad

Research Site, Bangalore

Research Site, Channai

Research Site, Kochi

Research Site, Mumbai

Research Site, New Dehli

Research SIte, Pune

Research Site, Holon

Research SIte, Tel Litwinsky

Research Site, Florence

Research Site, Milan

Research Site, Siena

Research Site, Chihuahua City

Research Site, Guadalajara

Research Site, Monterrey

Research Site, Lublin

Research Site, Szczecin

Research Site, Wroclaw

Research Site, Manatí

Research Site, Toa Baja

Research Site, Galati

Research Site, Oradea

Research Site, Târgu Mureş

Research Site, Arkhangelsk

Research Site, Moscow

Research Site, Rostov-on-Don

Research Site, Saint Petersburg

Research Site, Stavropol

Research Site, Bratislava

Research Site, Trebišov

Research Site, Johannesburg

Research Site, Kempton Park

Research Site, Midrand

Research Site, Soweto

Research Site, Busan

Research Site, Daegu

Research Site, Jeonju

Research Site, Seoul

Research Site, Sungnam

Research Site, Alicante

Research Site, Barcelona

Research Site, Madrid

Research Site, Seville

Research Site, Ankara

Research Site, Istanbul

Research Site, Sisli-Istanbul

Research Site, Bath

Research Site, Birmingham

Research Site, Edinburgh

Research Site, Frome

Research Site, Guildford

Research Site, Hull

Research Site, Sheffield

Research Site, Swansea

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

AstraZeneca

INDUSTRY